A Phase II Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Cotadutide in Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 54
- 试验地点
- 1
- 主要终点
- Number of Participants With Adverse Events (AEs).
研究概览
简要总结
The purpose of this study is to evaluate the safety and efficacy of cotadutide in participants with non-cirrhotic NASH with fibrosis.
详细描述
A Phase 2, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of two different doses of cotadutide at 300 and 600 μg in participants with non-cirrhotic non-alcoholic steatohepatitis with fibrosis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provision of informed consent
- •Males and female participants ≥ 18 to ≤ 75 years of age (inclusive) at the time of signing the informed consent.
- •Histologically confirmed non-alcoholic steatohepatitis (NASH) per NASH Clinical Research Network (CRN) criteria as diagnosed by histology from a liver biopsy performed ≤ 180 days from randomization and fulfilling all of the following histological criteria:
- •NAS (Non-alcoholic Fatty Liver Disease Activity Score) ≥ 4 with a score of ≥ 1 for each component: steatosis, lobular inflammation, and ballooning
- •Presence of fibrosis stage F2 or F3
- •Women of childbearing potential, non-pregnant and nonbreastfeeding and using appropriate birth control to avoid pregnancy throughout the study and for up to 4 weeks after the last dose of study intervention.
排除标准
- •Chronic liver disease of other etiologies.
- •History of cirrhosis and/or hepatic decompensation, including evidence of portal hypertension (e.g. low platelet count, splenomegaly, ascites, history of hepatic encephalopathy, esophageal varices, or variceal bleeding).
- •Clinically significant cardiovascular or cerebrovascular disease within 90 days prior to screening, including but not limited to, myocardial infarction, acute coronary syndrome, unstable angina pectoris, transient ischemic attack, or stroke, or participants who have undergone percutaneous coronary intervention or a coronary artery bypass graft within the past 90 days or who are due to undergo these procedures at the time of screening
- •History of malignant neoplasms within 5 years prior to screening, except for adequately treated basal cell, squamous cell skin cancer, or any in situ carcinoma.
- •Participation in another clinical study with an investigational product administered within the last 30 days or 5 half-lives of the therapy (whichever is longer) at the time of screening or the time of the historical biopsy or concurrent participation in another interventional study of any kind or prior randomization in this study.
- •Severe allergy/hypersensitivity to any of the proposed study treatments or excipients
- •Contraindication to liver biopsy (eg, bleeding diathesis, such as hemophilia, suspected hemangioma, or suspected echinococcal infection) or inability to safely obtain a liver biopsy as determined by the investigator
- •Severely uncontrolled hypertension defined as SBP ≥ 180 mmHg or DBP ≥ 110 mmHg on the average of 2 seated BP measurements after being at rest for at least 10 minutes at screening or randomization 9 Any positive results for human immunodeficiency virus infection, positive results for hepatitis B surface antigen or hepatitis C antibody test along with a positive HCV RNA test.
研究组 & 干预措施
Cotadutide 300μg
干预措施: Cotadutide (Drug)
Placebo 300μg
干预措施: Placebo (Drug)
Cotadutide 600μg
干预措施: Cotadutide (Drug)
Placebo 600μg
干预措施: Placebo (Drug)
结局指标
主要结局
Number of Participants With Adverse Events (AEs).
时间窗: First dose on Day 1 until the follow-up period, 28 days post last dose, up to approximately 52 weeks.
To assess safety and tolerability of Cotadutide. Occurrence of AEs and serious AEs, including AEs leading to dose reduction, and AEs of special interest.
Number of Participants With Abnormal Vital Signs.
时间窗: First dose on Day 1 until the follow-up period, 28 days post last dose, up to approximately 52 weeks.
To assess safety and tolerability of Cotadutide.
Number of Participants With Abnormal Laboratory Assessments
时间窗: First dose on Day 1 until the follow-up period, 28 days post last dose, up to approximately 52 weeks.
To assess safety and tolerability of Cotadutide.
Number of Participants With Treatment Emergent Abnormality in 12-lead Electrocardiogram (ECG).
时间窗: First dose on Day 1 until the follow-up period, 28 days post last dose, up to approximately 52 weeks.
To assess safety and tolerability of Cotadutide.
Number of Treatment-induced Anti-Drug Antibody (ADA) Participants
时间窗: First dose on Day 1 until the follow-up period, 28 days post last dose, up to approximately 52 weeks.
To assess the immunogenicity of Cotadutide
Titer of Treatment-induced Anti-Drug Antibody (ADA)
时间窗: From first dose on Day 1 until the follow-up period, 28 days post last dose (from randomization up to approximately 52 weeks).
To assess the immunogenicity of cotadutide. Titers represent a dilution and are therefore unitless. Summary statistics are based on the maximum observed titer for each ADA positive subject within the time frame.
次要结局
未报告次要终点